Intuniv 1mg, 2mg, 3mg, 4mg prolonged-release tablets
- Name:
Intuniv 1mg, 2mg, 3mg, 4mg prolonged-release tablets
- Company:
Shire Pharmaceuticals Ireland Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/07/20
(Click to Download)Click on this link to Download PDF directly
Shire Pharmaceuticals Ireland Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 13 July 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Improved presentation of SPC
- Updated inline with QRD template and/or excipient guideline
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
Section |
Changes (in red) |
|
Throughout |
Changed ‘Intuniv’ to ‘guanfacine’ |
|
Sections 2, 3, 6.1, 6.5, 8 |
Added ‘prolonged-release’ to description of product. Section 3 also moved wording of excipients |
|
4.4 Special warnings and precautions for use |
Added: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’. |
|
4.7. Effects on ability to drive and use machines |
Updated text: Guanfacine may have a moderate to severe influence on the ability to drive and use machines. Guanfacine can cause dizziness and somnolence. These effects occur predominantly at the start of treatment and may occur less frequently as treatment continues. Syncope has also been observed.
|
|
4.8. Undesirable effects |
HPRA information – removed address, email address and phone number information |
|
9. Date of first authorization/ renewal of the authorisation |
Date of first authorization: 17/09/2015 Date of latest renewal: 25/06/2020 |
|
10. DATE OF REVISION OF THE TEXT
|
25 June 2020 |
Updated on 13 July 2020 PIL
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to MA holder contact details
Updated on 2 July 2019 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.5 (Interaction with other medicinal products and other forms of interaction), register a non-clinical study V8953M-SPD503 (Transporter Interaction – OCT1 inhibition).
Updated on 21 February 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 21 February 2018 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 20 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 20 February 2018 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 28 June 2017 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition of the undesirable effect of Erectile Dysfunction in section 4.8, with a frequency of “Not known”
Subsequent update to the date of revision of the text.
Updated on 26 June 2017 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 22 December 2016 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 22 December 2016 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
This variation covered a revision to the Product Information in response to a single, well characterized postmarketing case of hypertensive encephalopathy upon abrupt discontinuation of Intuniv (guanfacine hydrochloride) in Canada. The Posology and Method of Administration, Special Warnings and Precautions for Use, and Undesirable Effects sections of the Intuniv SmPC have been updated to include the risk of withdrawal blood pressure, increase/rebound hypertension and heart rate increase, and in very rare cases, hypertensive encephalopathy upon abrupt discontinuation of Intuniv.
Updated on 24 October 2016 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Amended (Sections 4.5 & 5.2), to include information on MATE1 and OCT1 inhibition.
Updated on 21 October 2016 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 13 April 2016 SPC
Reasons for updating
- New SPC for new product
- New SPC for medicines.ie
- Addition of joint SPC covering all presentations
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 11 April 2016 PIL
Reasons for updating
- New PIL for new product
- New PIL for medicines.ie
Updated on 11 April 2016 PIL
Reasons for updating
- Correction of spelling/typing errors